Cancer cells consume more sugar than an average cell and are therefore considered more sensitive to insulin. Insulin is used to potentiate chemotherapy. It does so by attaching itself to the cancerous cells, making them more permeable and thus increasing the toxic effect of chemotherapy on these cells. This makes it easier to target cancer cells since the excess insulin activators are activated. IPT may also reduce chemotherapy doses, thus reducing the chemo’s side effects.
Low-Dose Chemotherapy with Insulin (IPT) in Combination with Hormone Therapy for Treatment of Castration-Resistant Prostate Cancer
Purpose. To evaluate the results and quality of life of patients with resistant of castration-resistant tumors previously treated with Insulin-potentiation therapy (IPT) combined with hormone therapy.
Materials and methods. Sixteen patients with metastasis prostate tumors after bilateral castration, androgenic blockade, and progression of the disease were observed during the study. The patients were divided into two groups: group A consisting of 8 patients treated with low-dose chemotherapy Epirubicin, Vinblastine, and Cyclophosphamide combined with LHRH agonist and group B consisting of another 8 patients treated with low-dose chemotherapy Docetaxel combined with LHRH agonist.
Results. The overall (groups A and B) results concerning PSA after the sixth IPT show partial effect in 8 out of 16 (50%) patients, stabilization in 4 out of 16 (25%), and progression in 4 out of 16 (25%). The median survival for all treated patients is 11,7 months (range 3–30 months). During the treatment no significant side effects were observed, and no lethal cases occurred.
Conclusion. In spite of the small number of the treated patients with castration-resistant prostate tumors, the preliminary results are promising and this gives us hope and expectations for future serious multicenter research over the possibilities for routine implementation of IPTLD.